he added capacity will further enhance WuXi Biologics’ commercial manufacturing capabilities in the U.S. The site is expected to employ 250 people...
HistoSonics, , the manufacturer of the non-invasive Edison® Histotripsy System, announced a patient from the University of Rochester Medical Cent...
“It’s an honor to be named in the Dow Jones Sustainability Indices for a ninth consecutive year. I am particularly proud of our team’s pr...
QIAGEN announced a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase tha...
QIAGEN announced a strategic plan to step up investments over the next five years in its market-leading QIAGEN Digital Insights (QDI) business. These inve...
Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) product...
The priority categorization, established by the WHO in collaboration with UNICEF and the Revolving Fund of the Pan American Health Organization, is based o...
-Sail Biomedicines, Inc. (“Sail” or the “Company”), a Flagship Pioneering company and leader in RNA-based programmable medicines, a...
Inaugural strategy is one of the largest ever first-time private life sciences growth funds Fundraise closed above its original target, reflecting stron...
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company ded...
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development...
Tome Biosciences, Inc., the programmable genomic integration (PGI) company, announces that it has acquired Replace Therapeutics Inc., a private biote...
The transformative point of care solution will complement Roche’s centralised diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coa...
Cell BioEngines, Inc., a clinical-stage biotechnology company focused on delivering novel, innovative stem cell and immune cell therapies to address blood ...
© 2025 Biopharma Boardroom. All Rights Reserved.
